Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100

Biochemical Pharmacology

Volumn 77, Issue 5, 2009, Pages 910-919

  Yu, Rosie Z ^a   Lemonidis, Kristina M ^a   Graham, Mark J ^a   Matson, John E ^a   Crooke, Rosanne M ^a   Tribble, Diane L ^a   Wedel, Mark K ^a   Levin, Arthur A ^a   Geary, Richard S ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense; ApoB; Cross species; Lipid lowering; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; CHOLESTEROL; ISIS 147764; ISIS 326358; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MIPOMERSEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG TARGETING; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; LIVER LEVEL; MALE; MONKEY; MOUSE; NONHUMAN; NORMAL HUMAN; PARTITION COEFFICIENT; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SPECIES DIFFERENCE; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEIN B-100; BASE SEQUENCE; HALF-LIFE; HUMANS; MACACA FASCICULARIS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECIES SPECIFICITY;

EID: 59749087965     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.11.005     Document Type: Article

References (39)

1. Galluppi G.R., Rogge M.C., Roskos L.K., Lesko L.J., Green M.D., Feigal Jr. D.W., et al. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther 69 (2001) 387-399
2. Geary R.S., Yu R.Z., Siwkowski A., and Levin A.A. Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man. In: Crooke S.T. (Ed). Antisense drug technology: principles, strategies and applications (2007), Taylor & Francis Group, Boca Raton, FL 305-326
3. Callies S., Andre V., Vick A.-M., Graff J., Patel B., Brail L., et al. Modelling pharmacokinetic and pharmacodynamic properties of second generation antisense-oligonucleotides (ASOs) (2007), PAGE (Population Approach Group in Europe), Copenhagen
4. Yu RZ, Gibiansky L, Gibiansky E, Geary RS. Population pharmacokinetics and pharmacodynamics of ISIS 2302 (Role of Population Analysis in Drug Development). ASCPT Annual Meeting. Orlando, Florida; 2001.
5. Yu RZ, Matson J, Geary RS. Terminal elimination rates for antisense oligonucleotides in plasma correlate with tissue clearance rates in mice and monkeys. Annual Meeting of American Association of Pharmaceutical Scientists. Denver, Colorado; 2001.
6. Geary R.S., Mathison B., Ushiro-Watanabe T., Savides M.C., Henry S.P., and Levin A.A. Second generation antisense oligonucleotide pharmacokinetics and mass balance following intravenous administration in rats (2001), Society of Toxicology, Oxford University Press, San Francisco, CA p. 343
7. Geary R.S., Ushiro-Watanabe T., Truong L., Freier S.M., Lesnik E.A., Sioufi N.B., et al. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296 (2001) 890-897
8. Geary R.S., Yu R.Z., Watanabe T., Henry S.P., Hardee G.E., Chappell A., et al. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 31 (2003) 1419-1428
9. Yu R.Z., Kim T.-W., Hong A., Watanabe T.A., Gaus H.J., and Geary R.S. Cross-species pharmacokinetic comparison from mouse to man of a second generation antisense oligonucleotide ISIS 301012. Targeting human ApoB-100. Drug Metab Dispos 35 (2007) 460-468
10. Levin A.A., Yu R.Z., and Geary R.S. Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: Crooke S.T. (Ed). Antisense drug technology: principles, strategies and applications (2007), Taylor & Francis Group, Boca Raton, FL 183-215
11. Crooke S.T., Vickers T., Lima W., and Wu H. Mechanisms of antisense drug action, an introduction. In: Crooke S.T. (Ed). Antisense drug technology: principles, strategies and applications (2007), Taylor & Francis Group, Boca Raton, FL 5-46
12. Wu H., Lima W., and Crooke S.T. Molecular cloning and expression of cDNA for human RNase H. Antisense Nucleic Acid Drug Dev 8 (1998) 53-61
13. Wu H., MacLeod A.R., Lima W.F., and Crooke S.T. Identification and partial purification of human double strand RNase activity: a novel terminating mechanism for oligoribonucleotide antisense drugs. J Biol Chem 273 (1998) 2532-2542
14. Davidson N.O., and Shelness G.S. Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 20 (2000) 169-193
15. Marsh J.B., Welty F.K., Lichtenstein A.H., Lamon-Fava S., and Schaefer E.J. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 162 (2002) 227-244
16. Das H.K., Leff T., and Breslow J.L. Cell type-specific expression of the human apoB gene is controlled by two cis-acting regulatory regions. J Biol Chem 263 (1988) 11452-11458
17. Crooke R. Second-generation antisense drug for cardiovascular disease demonstrates significant and durable reductions in cholesterol. The 9th Drug Discovery Technology World Congress. Boston, MA (2004)
18. Crooke R.M., Graham M.J., Lemonidis K.M., Whipple C.P., Koo S., and Perera R.J. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 46 (2005) 872-884
19. Henry S.P., Stecker K., Brooks D., Monteith D., Conklin B., and Bennett C.F. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther 292 (2000) 468-479
20. McKay R.A., Miraglia L.J., Cummins L.L., Owens S.R., Sasmor H., and Dean N.M. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression. J Biol Chem 274 (1999) 1715-1722
21. Altmann K.-H., Fabbro D., Dean N.M., Geiger T., Monia B.P., Muuler M., et al. Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal transduction inhibitors. Biochem Soc Trans 24 (1996) 630-637
22. Baker B.F., Lot S.S., Condon T.P., Cheng-Flournoy S., Lesnik E.A., Sasmor H.M., et al. 2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 272 (1997) 11994-12000
23. Stein E. High low-density lipoprotein cholesterol on three drugs. ACC06: 56th Scientific Session of the American College of Cardiology ACC Symposium: Common challenges in preventive cardiology; 2007. p. 603-8.
24. Stein E., Wedel M., and Bradley J. Statin-like dose-dependent reductions in LDL cholesterol and apolipoprotein B with ISIS, 301012, an antisense inhibitor of apolipoprotein B, in subjects with polygenic hypercholesterolemia. J Am Coll Cardiol 49 (2007) 1206-1278
25. Kastelein J., and Akdim F. Trip M. ISIS, 301012, an antisense inhibitor of apolipoprotein B, produces significant additional reduction of low-density lipoprotein cholesterol and apolipoprotein B in hypercholesterolemic subjects on statins not meeting target. J Am Coll Cardiol 49 (2007) 820-827
26. Kastelein J.J., Wedel M.K., Baker B.F., Su J., Bradley J.D., Yu R.Z., et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114 (2006) 1729-1735
27. Leeds J.M., Graham M.J., Troung L., and Cummins L.L. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem 235 (1996) 36-43
28. Yu R.Z., Baker B., Chappel A., Geary R.S., Chueng E., and Levin A.A. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 304 (2002) 19-25
29. Geary R.S., Leeds J.M., Henry S.P., Monteith D.K., and Levin A.A. Antisense oligonucleotide inhibitors for the treatment of cancer. 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 12 (1997) 383-393
30. Zhang R.W., Iyer R.P., Yu D., Tan W.T., Zhang X.S., Lu Z.H., et al. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. J Pharmacol Exp Ther 278 (1996) 971-979
31. Geary R.S., Yu R.Z., Leeds J.M., Ushiro-Watanabe T., Henry S.P., Levin A.A., et al. Pharmacokinetic properties in animals. In: Crooke S.T. (Ed). Antisense drug technology: principles, strategies, and applications (2001), Marcel Dekker Inc., New York 119-154
32. Geary R.S., Yu R.Z., and Levin A.A. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs 2 (2001) 562-573
33. Yu R.Z., Geary R.S., and Levin A.A. Pharmacokinetics and pharmacodynamics of antisense oligonucleotides. In: Meyers R.A. (Ed). Encyclopedia of molecular cell biology and molecular medicine (2007), Wiley-VCH, Weinheim, Germany
34. Boothe D.M., Boeckh A., Simpson R.B., and Dubose K. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. J Vet Intern Med 20 (2006) 1297-1306
35. Svetyi L.I., and Alekhin S.N. Pharmacokinetic and pharmacodynamic effects of isradipine in patients with arterial hypertension. Eksp Klin Farmakol 65 (2002) 35-38
36. Zhou H., Choi L., Lau H., Bruntsch U., Vries E.E., Eckhardt G., et al. Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers. J Clin Pharmacol 40 (2000) 275-283
37. Ebert U., Grossmann M., Oertel R., Gramatte T., and Kirch W. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. J Clin Pharmcol 41 (2001) 51-60
38. Yu R.Z., Zhang H., Geary R.S., Graham M., Masarjian L., Lemonidis K., et al. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J Pharmacol Exp Ther 296 (2001) 388-395
39. Barrett J.S., Gupta M., and Mondick J.T. Model-based drug development applied to oncology. Expert Opin Drug Discov 2 (2007) 185-209